Maryland biotechnology firms Profectus BioSciences Inc. and Emergent BioSolutions Inc. will receive up to $36 million to develop and manufacture a new vaccine against a type of virus that causes hemorrhagic fever.
SUBSCRIBE
Biohealth Innovation
Founding Member of
